Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
The purpose of this study is to explore the activity of ZD1839 added to concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally advanced head and neck cancer. Activity is described in terms of response rate (complete responses only).
Head and Neck Cancer
DRUG: ZD 1839 500mg
Complete Response Rate Achieved 1 Month After Concurrent Chemotherapy and Radiation Treatment, To explore the activity of ZD1839 added to concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally advanced head and neck cancer. Activity is described in terms of response rate (complete responses only)., 1 month
4 Year Overall Survival, Percentage of patients who survived 4 years or more, 0.3 to 4.7 years|4 Year Progression Free Survival, Percentage of patients who survived without progressive disease 4 years or more, 0.3 to 4.7 years|4 Year Disease Specific Survival, Percentage of patients who did not die by the disease within 4 years, 0.3 to 4.7 years
The purpose of this study is to explore the activity of ZD1839 added to concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally advanced head and neck cancer. Activity is described in terms of response rate (complete responses only).